JP2007520537A5 - - Google Patents

Download PDF

Info

Publication number
JP2007520537A5
JP2007520537A5 JP2006551904A JP2006551904A JP2007520537A5 JP 2007520537 A5 JP2007520537 A5 JP 2007520537A5 JP 2006551904 A JP2006551904 A JP 2006551904A JP 2006551904 A JP2006551904 A JP 2006551904A JP 2007520537 A5 JP2007520537 A5 JP 2007520537A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
chlorophenylamino
amide
carboxylic acid
acceptable derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006551904A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007520537A (ja
Filing date
Publication date
Priority claimed from GBGB0402356.0A external-priority patent/GB0402356D0/en
Application filed filed Critical
Publication of JP2007520537A publication Critical patent/JP2007520537A/ja
Publication of JP2007520537A5 publication Critical patent/JP2007520537A5/ja
Withdrawn legal-status Critical Current

Links

JP2006551904A 2004-02-03 2005-02-01 免疫病または炎症障害を治療するためのカンナビノイド2受容体の調節剤としての2−(フェニルアミノ)−ピリミジン−5−アミド Withdrawn JP2007520537A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0402356.0A GB0402356D0 (en) 2004-02-03 2004-02-03 Novel compounds
PCT/GB2005/000341 WO2005075440A1 (en) 2004-02-03 2005-02-01 2- (phenylamino) -pyrimidin-5-amides as cannabinoid 2 receptors modulators for the treatment of immune or inflammatory disorders

Publications (2)

Publication Number Publication Date
JP2007520537A JP2007520537A (ja) 2007-07-26
JP2007520537A5 true JP2007520537A5 (cg-RX-API-DMAC7.html) 2008-03-21

Family

ID=31985568

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006551904A Withdrawn JP2007520537A (ja) 2004-02-03 2005-02-01 免疫病または炎症障害を治療するためのカンナビノイド2受容体の調節剤としての2−(フェニルアミノ)−ピリミジン−5−アミド

Country Status (5)

Country Link
US (1) US20090264452A1 (cg-RX-API-DMAC7.html)
EP (1) EP1711475A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007520537A (cg-RX-API-DMAC7.html)
GB (1) GB0402356D0 (cg-RX-API-DMAC7.html)
WO (1) WO2005075440A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007125049A1 (en) * 2006-04-27 2007-11-08 Solvay Pharmaceuticals Gmbh Use of cbx cannabinoid receptor modulators as potassium channel modulators
US7763607B2 (en) 2006-04-27 2010-07-27 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
CA2757188A1 (en) 2009-03-30 2010-10-07 Astellas Pharma Inc. Pyrimidine compound
CN113109571B (zh) * 2021-03-19 2023-05-05 浙江工商大学 一种用于评估个体过敏程度的试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112820A (en) * 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
HUT63941A (en) * 1992-05-15 1993-11-29 Hoechst Ag Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same
JPH11512399A (ja) * 1995-09-01 1999-10-26 シグナル ファーマシューティカルズ,インコーポレイテッド ピリミジンカルボキサミドおよび関連化合物ならびに炎症状態を処置するための方法
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
CZ20032233A3 (cs) * 2001-02-20 2004-12-15 Bristol-Myers Squibb Company Derivát 2,4-disubstituovaného pyrimidin-5-karboxamidu jako modulátor draslíkového kanálku KCNQ
JP2005539036A (ja) * 2002-08-21 2005-12-22 グラクソ グループ リミテッド ピリミジン化合物
UY27939A1 (es) * 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
GB0222495D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
GB0222493D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds

Similar Documents

Publication Publication Date Title
RU2293731C2 (ru) Производные пиридина и пиримидина, способы их получения (варианты), фармацевтическая композиция и применение
JP6542212B2 (ja) ブロモドメイン阻害剤としての新規キナゾリノン
CN101679287B (zh) 烟碱型乙酰胆碱受体调节剂
JP2007520539A5 (cg-RX-API-DMAC7.html)
KR101562835B1 (ko) 치료제
TWI224102B (en) Serotonergic agents
JP2008513498A5 (cg-RX-API-DMAC7.html)
JP2008513516A5 (cg-RX-API-DMAC7.html)
AU2016370554A1 (en) Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
JP2013537887A5 (cg-RX-API-DMAC7.html)
JP2005526723A5 (cg-RX-API-DMAC7.html)
JP2010506851A (ja) 二環式ヘテロ芳香族化合物
MXPA04007502A (es) Derivados de quinolina como antagonistas de neuropeptido y (npy).
JP2008500336A (ja) 治療化合物:骨格としてのピリジン
JP2008501758A5 (cg-RX-API-DMAC7.html)
ES2222396T3 (es) Compuestos utiles como ingrediente activo de un medicamento para el tratamiento preventivo y/o terapeutico de enfermedades neurodegenerativas.
CN107108478A (zh) Urat1抑制剂
JP6929857B2 (ja) 6,7,8,9−テトラヒドロ−5H−ピリド[2,3−d]アゼピンドーパミンD3リガンド
JP5822079B2 (ja) 疼痛治療剤
JP2008543782A (ja) 5−ht1a受容体のピペラジン−ピペリジンアンタゴニストおよびアゴニスト
JP2014518281A (ja) 電位依存性ナトリウムチャネル遮断薬
JP2009542661A5 (cg-RX-API-DMAC7.html)
JP4885709B2 (ja) ピリジニルアセトニトリル類
JP2007523206A5 (cg-RX-API-DMAC7.html)
JPWO2008029924A1 (ja) 環状アミノアルキルカルボキサミド誘導体